Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

This valuable study presents a mouse gastruloid model that can be used to generate hematopoietic progenitors as well as leukemic cells. However, in its current form, the manuscript is inadequate ...

Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial.The study was put on hold due to grade 5 events among patients who received inotuzumab ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 Series B Financing Funds AUTX-703 Development through Phase 1 Clinical ...

The society also recognized Tampa General and its academic partnership with the USF Health Morsani College of Medicine, which forms a multidisciplinary facility with all-encompassing cancer care that ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia (AML) or myelodysplastic syndrome ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for myelodysplastic ...